Skip to main content
Premium Trial:

Request an Annual Quote

Variagenics Signs Three New Licenses For Cardiovascular Disease Gene

NEW YORK, Jan. 16-Variagenics said today that it has licensed its patents on the methylenetetrahydrofolate reductase gene to GeneOhm Sciences, Sciona, and Tm Bioscience. Variations in the MTHFR gene may be related to thromboembolic disease risk.

 

The licenses are worldwide and non-exclusive, and give each of the three companies the right to commercialize tests that identify polymorphisms in the gene.

 

Variagenics retains the right to develop tests relating to other diseases that involve the MTHFR gene.

 

Yesterday, the company announced a similar dealwith Celera Diagnostics.

 

GeneOhm, a California startup, is developing a chip-based technology to identify polymorphisms by interruptions in the flow of electrical current.

 

Sciona is a British diagnostics and pharmacogenomics firm.

 

Tm Bioscience, based in Toronto, is developing a battery of SNP diagnostic tests.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.